Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...

People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus for certain participants in recent trials in Africa and Europe A digital ...

In the United States, HIV continues to be a significant cause of morbidity and mortality. In 2023, more than 39,000 people were diagnosed with HIV, and approximately 4,500 people died from causes ...

The key theme of the 20th International AIDS Conference, which recently concluded in Melbourne, Australia, was "stepping up the pace" to broaden global access to HIV testing and treatment, but ...

Please provide your email address to receive an email when new articles are posted on . Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to ...

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...